A Revance Therapeutics securities class action settlement of $17,000,000 has been reached covering investors who purchased or acquired Revance Therapeutics common stock (ticker: RVNC) or 1.75% fixed coupon convertible senior unsecured notes between February 29, 2024 and February 6, 2025 — the period surrounding the Crown Laboratories merger. Individual payout amounts will depend on the total number of valid claims submitted and the allocation plan approved by the court. Proof documentation is required to file. The official claim deadline is August 28, 2026 — submit your claim through the verified form before that date.